Companies:

 

Articles:

 
Biotech

Orthocell records first sales of Striate+ dental membrane in new European markets

Go to Imelda Cotton author's page
By Imelda Cotton - 
Orthocell ASX OCC first sales Striate+ dental membrane European markets
Copied

Orthocell (ASX: OCC) has achieved the first sales of its dental guided bone and tissue regeneration product Striate+ into new markets in Germany, Austria and Switzerland through exclusive global distribution partner BioHorizons Implant Systems, one of the world’s largest dental implant companies.

BioHorizons subsidiary BioHorizons Camlog, which is responsible for the marketing and distribution of Striate+ in the European Union and UK, conducted the regional launch and first sales.

Orthocell expects expansion into these regions will significantly increase revenue opportunities, with the company aiming for a 20% share of a targeted addressable market valued at more than $1 billion.

Current markets

Striate+ is approved for use in the US, Australia, New Zealand, Europe, the UK and Canada, with BioHorizons the exclusively distributor in these markets.

“Overwhelmingly positive” feedback for the product from dental surgeons and a 98.6% success rate in a recent post-market clinical study have fuelled strong sales growth in these existing markets.

Orthocell also attributes the high adoption and early market success of Striate+ to its unique features, which include ease of use, ability to conform to treatment surfaces and promotion of more efficient bone growth.

Fast-track expansion

Orthocell is now working on a fast-track expansion of Striate+ into large and attractive markets where BioHorizons has established accounts and distribution networks.

Singapore’s Health Sciences Authority gave the company authority to commence sales in the region earlier this month.

Orthocell anticipates regulatory approval for use of the product in Brazil within the next three months.

Collagen membrane

Striate+ is a sterile, resorbable collagen membrane for use in dental bone and tissue regeneration applications, including dental implant procedures.

The single-stage surgical product aims to protect bone defects from the in-growth of gingival tissue, provide a favourable environment for osteogenesis and assure reliable formation of high-quality bone.

Orthocell produces Striate+ in Australia using a proprietary SMRT manufacturing process that preserves the collagen structure without crosslinking or chemical modification for optimal tissue integration.